logo
GSK and Lifetime ® launch original movie to raise awareness about the impact of meningitis

GSK and Lifetime ® launch original movie to raise awareness about the impact of meningitis

Business Wire09-05-2025

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m. CT, Pretty Hurts features a storyline that aims to raise awareness among parents about meningococcal disease, known as meningitis, an uncommon but serious illness that teens and young adults aged 16-23 are at an increased risk for. 1,2,3 GSK provided financial and content support for the film, which alerts moms that while many teens have received vaccination against meningitis serogroups A, C, W, and Y, many may be missing meningitis B vaccination. 4
The film follows Julie, played by actress Haylie Duff, a relatable mom juggling the demands of family life and a career, while navigating the challenges of parenting a teen in high school. After Julie's daughter, Lauren, enters a beauty pageant to win scholarship money for college, meningitis suddenly strikes close to home, showcasing the impact of the disease on both their family and an entire community.
As the newest spokesperson for the larger Ask2BSure campaign, Alyson Hannigan, seasoned actress and mom to a 16-year-old, knows parenting teens is a job with no script. Hannigan was moved to join Ask2BSure after hearing the real stories of families impacted by meningitis. GSK honors the experiences of those families with this Lifetime movie.
Hannigan said: 'As a mom, I know how hard it can be to stay on top of everything, especially when it comes to my teen's health, and it is so important to ask the right questions about meningitis risk and vaccination. I'm proud to have joined the Ask2BSure campaign so that I can empower other parents to speak up and ask their teen's doctor for more information.' 4
Pretty Hurts builds off the 2023 GSK and Lifetime co-branded short film, 'I Never Thought to Ask: A Mom's Quest for Answers,' which also brought awareness to meningitis B and vaccination.
Cynthia Burman, US Medical Affairs Lead for Neisseria Vaccines for GSK, said: 'Working with Lifetime on this longer-form creative and educational film allows us to deliver impactful content to help empower parents in the US to start the conversation with their teen's doctor to find out if their teen is missing any meningococcal vaccinations.' 4,5
Pretty Hurts is intended for viewers in the US. The movie premieres on Lifetime on June 28 at 8 p.m. ET and will be available for viewing starting June 29 on MyLifetime.com/movies.
About GSK's Ask2BSure Campaign
Ask2BSure aims to educate and empower parents of teens and young adults to start meningitis conversations with their teen's doctors and 'ask to be sure' their teen has received vaccination to help protect against all five vaccine-preventable serogroups of meningitis. Vaccination may not protect all recipients. Find out more at Ask2BSure.com.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in GSK's Annual Report on Form 20-F for 2024.
References:
1. Centers for Disease Control and Prevention. Risk Factors for Meningococcal Disease. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/risk-factors/index.html#cdc_risk_factors_who-people-at-increased-risk. Accessed May 2025.
2. Centers for Disease Control and Prevention. Meningococcal Disease Surveillance and Trends. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/php/surveillance/index.html. Accessed May 2025.
3. Centers for Disease Control and Prevention. Clinical Overview of Meningococcal Disease. Available at https://www.cdc.gov/meningococcal/hcp/clinical/index.html. Accessed May 2025.
4. Pingali C, Yankey D, Chen M, et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2023. MMWR Morb Mortal Wkly Rep 2024; 73:708–714. Available at: https://www.cdc.gov/mmwr/volumes/73/wr/mm7333a1.htm. Accessed May 2025.
5. Centers for Disease Control and Prevention. Meningococcal Vaccination for Adolescents: Information for Healthcare Professionals. Available at: https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/?CDC_AAref_Val=https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Accessed May 2025.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Molina Healthcare (MOH) Receives a Buy from Bernstein
Molina Healthcare (MOH) Receives a Buy from Bernstein

Business Insider

time5 hours ago

  • Business Insider

Molina Healthcare (MOH) Receives a Buy from Bernstein

In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Molina Healthcare (MOH – Research Report), with a price target of $414.00. The company's shares closed today at $296.88. Confident Investing Starts Here: According to TipRanks, Wilkes is a 2-star analyst with an average return of -0.3% and a 42.86% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. In addition to Bernstein, Molina Healthcare also received a Buy from Wells Fargo's Stephen Baxter in a report issued yesterday. However, on June 3, Barclays maintained a Hold rating on Molina Healthcare (NYSE: MOH). Based on Molina Healthcare's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.15 billion and a net profit of $298 million. In comparison, last year the company earned a revenue of $9.93 billion and had a net profit of $301 million Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year. Last month, Dale Wolf, a Director at MOH sold 1,500.00 shares for a total of $484,328.00.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

time11 hours ago

  • Yahoo

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Enovis to Participate in Upcoming Investor Conferences
Enovis to Participate in Upcoming Investor Conferences

Yahoo

time12 hours ago

  • Yahoo

Enovis to Participate in Upcoming Investor Conferences

Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time. Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meetings on Tuesday, June 17th. A link to the live audio webcasts, if available, as well as a replay of these events, will be available on the Company's website under the Investors tab at Events and Presentations. ABOUT ENOVIS Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Contact: Kyle RoseVice President, Investor RelationsEnovis Corporationinvestorrelations@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store